Raras
Buscar doenças, sintomas, genes...
Síndrome epilepsia de início na infância
ORPHA:98259PCDT · SUSDOENÇA RARA

Uma síndrome epiléptica que acontece na infância.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma síndrome epiléptica que acontece na infância.

Publicações científicas
11 artigos
Último publicado: 2026 Mar
Medicamentos
3 registrados
RUFINAMIDE, CANNABIDIOL, TOPIRAMATE

Tem tratamento?

3 medicamentos registrados
Ver detalhes, fases e interações →
RUFINAMIDECANNABIDIOLTOPIRAMATE
🏥
SUS: Cobertura mínimaScore: 30%
PCDT disponível
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
101 sintomas
🦴
Ossos e articulações
13 sintomas
😀
Face
11 sintomas
👁️
Olhos
10 sintomas
💪
Músculos
8 sintomas
🛡️
Imunológico
4 sintomas

+ 120 sintomas em outras categorias

Características mais comuns

Deficiência intelectual, moderada
Letargia
Fala hipernasal
Sinusite
EEG com ondas de espícula focais parietais
EEG com ondas agudas parietais
281sintomas
Sem dados (281)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 281 características clínicas mais associadas, ordenadas por frequência.

Deficiência intelectual, moderadaIntellectual disability, moderate
LetargiaLethargy
Fala hipernasalHypernasal speech
SinusiteSinusitis
EEG com ondas de espícula focais parietaisEEG with parietal focal spike waves

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico11PubMed
Últimos 10 anos7publicações
Pico20252 papers
Linha do tempo
2026Hoje · 2026🧪 2010Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

37 genes identificados com associação a esta condição.

SCN3ASodium channel protein type 3 subunit alphaDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Pore-forming subunit of Nav1.3, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

LOCALIZAÇÃO

Cell membraneBasal cell membrane

VIAS BIOLÓGICAS (3)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisationSensory perception of sweet, bitter, and umami (glutamate) taste
MECANISMO DE DOENÇA

Epilepsy, familial focal, with variable foci 4

An autosomal dominant form of epilepsy characterized by focal seizures arising from different cortical regions, including the temporal, frontal, parietal, and occipital lobes. Seizure types commonly include temporal lobe epilepsy, frontal lobe epilepsy, and nocturnal frontal lobe epilepsy. Some patients may have intellectual disability or autism spectrum disorders. Seizure onset usually occurs in the first or second decades, although later onset has been reported, and there is phenotypic variability within families. A subset of patients have structural brain abnormalities. Penetrance of the disorder is incomplete. FFEVF4 is characterized by onset of focal seizures in the first years of life.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
13.0 TPM
Cerebelo
11.3 TPM
Hipotálamo
9.3 TPM
Brain Nucleus accumbens basal ganglia
8.5 TPM
Pituitária
8.1 TPM
OUTRAS DOENÇAS (5)
epilepsy, familial focal, with variable foci 4developmental and epileptic encephalopathy, 62genetic developmental and epileptic encephalopathyfamilial focal epilepsy with variable foci
HGNC:10590UniProt:Q9NY46
RELNReelinCandidate gene tested inAltamente restrito
FUNÇÃO

Extracellular matrix serine protease secreted by pioneer neurons that plays a role in layering of neurons in the cerebral cortex and cerebellum by coordinating cell positioning during neurodevelopment. Regulates microtubule function in neurons and neuronal migration. Binding to the extracellular domains of lipoprotein receptors VLDLR and LRP8/APOER2 induces tyrosine phosphorylation of DAB1 and modulation of TAU phosphorylation. Affects migration of sympathetic preganglionic neurons in the spinal

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (1)
Reelin signalling pathway
MECANISMO DE DOENÇA

Lissencephaly 2

A classic type lissencephaly associated with ataxia, intellectual disability, seizures and abnormalities of the cerebellum, hippocampus and brainstem.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
161.3 TPM
Cerebelo
101.1 TPM
Nervo tibial
38.5 TPM
Tireoide
4.3 TPM
Hipotálamo
3.8 TPM
OUTRAS DOENÇAS (3)
Norman-Roberts syndromeautosomal dominant epilepsy with auditory featuresfamilial temporal lobe epilepsy 7
HGNC:9957UniProt:P78509
MICAL1[F-actin]-monooxygenase MICAL1Candidate gene tested inTolerante
FUNÇÃO

Monooxygenase that promotes depolymerization of F-actin by mediating oxidation of specific methionine residues on actin to form methionine-sulfoxide, resulting in actin filament disassembly and preventing repolymerization (PubMed:29343822). In the absence of actin, it also functions as a NADPH oxidase producing H(2)O(2) (PubMed:21864500, PubMed:26845023, PubMed:29343822). Acts as a cytoskeletal regulator that connects NEDD9 to intermediate filaments. Also acts as a negative regulator of apoptosi

LOCALIZAÇÃO

CytoplasmCytoplasm, cytoskeletonEndosome membraneMidbody

VIAS BIOLÓGICAS (1)
Factors involved in megakaryocyte development and platelet production
EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Ectocervix
154.7 TPM
Sangue
152.9 TPM
Baço
149.7 TPM
Cervix Endocervix
135.5 TPM
Bladder
125.8 TPM
OUTRAS DOENÇAS (1)
autosomal dominant epilepsy with auditory features
HGNC:20619UniProt:Q8TDZ2
CRHCorticoliberinCandidate gene tested inTolerante
FUNÇÃO

Hormone regulating the release of corticotropin from pituitary gland (By similarity). Induces NLRP6 in intestinal epithelial cells, hence may influence gut microbiota profile (By similarity)

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (3)
G alpha (s) signalling eventsClass B/2 (Secretin family receptors)MECP2 regulates transcription of neuronal ligands
EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
12.2 TPM
Brain Anterior cingulate cortex BA24
9.8 TPM
Córtex cerebral
8.3 TPM
Hipotálamo
6.2 TPM
Cérebro - Amígdala
3.5 TPM
OUTRAS DOENÇAS (1)
autosomal dominant nocturnal frontal lobe epilepsy
HGNC:2355UniProt:P06850
CABP4Calcium-binding protein 4Candidate gene tested inTolerante
FUNÇÃO

Involved in normal synaptic function through regulation of Ca(2+) influx and neurotransmitter release in photoreceptor synaptic terminals and in auditory transmission. Modulator of CACNA1D and CACNA1F, suppressing the calcium-dependent inactivation and shifting the activation range to more hyperpolarized voltages (By similarity)

LOCALIZAÇÃO

CytoplasmPresynapse

MECANISMO DE DOENÇA

Cone-rod synaptic disorder, congenital non-progressive

A non-progressive retinal disorder characterized by stable low vision, nystagmus, photophobia, a normal or near-normal fundus appearance, and no night blindness.

OUTRAS DOENÇAS (2)
cone-rod synaptic disorder, congenital nonprogressiveautosomal dominant nocturnal frontal lobe epilepsy
HGNC:1386UniProt:P57796
SCN1ASodium channel protein type 1 subunit alphaCandidate gene tested inAltamente restrito
FUNÇÃO

Pore-forming subunit of Nav1.1, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisation
MECANISMO DE DOENÇA

Generalized epilepsy with febrile seizures plus 2

A rare autosomal dominant, familial condition with incomplete penetrance and large intrafamilial variability. Patients display febrile seizures persisting sometimes beyond the age of 6 years and/or a variety of afebrile seizure types. This disease combines febrile seizures, generalized seizures often precipitated by fever at age 6 years or more, and partial seizures, with a variable degree of severity.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
15.1 TPM
Cérebro - Hemisfério cerebelar
10.7 TPM
Cerebelo
9.3 TPM
Córtex cerebral
8.9 TPM
Hipotálamo
6.3 TPM
OUTRAS DOENÇAS (13)
developmental and epileptic encephalopathy, 6Ageneralized epilepsy with febrile seizures plus, type 2developmental and epileptic encephalopathy 6Bfamilial hemiplegic migraine
HGNC:10585UniProt:P35498
AP2M1AP-2 complex subunit muCandidate gene tested inAltamente restrito
FUNÇÃO

Component of the adaptor protein complex 2 (AP-2) (PubMed:12694563, PubMed:12952941, PubMed:14745134, PubMed:14985334, PubMed:15473838, PubMed:31104773). Adaptor protein complexes function in protein transport via transport vesicles in different membrane traffic pathways (PubMed:12694563, PubMed:12952941, PubMed:14745134, PubMed:14985334, PubMed:15473838, PubMed:31104773). Adaptor protein complexes are vesicle coat components and appear to be involved in cargo selection and vesicle formation (Pu

LOCALIZAÇÃO

Cell membraneMembrane, coated pit

VIAS BIOLÓGICAS (10)
Gap junction degradationFormation of annular gap junctionsRetrograde neurotrophin signallingVLDLR internalisation and degradationLDL clearance
MECANISMO DE DOENÇA

Intellectual developmental disorder, autosomal dominant 60, with seizures

An autosomal dominant disorder characterized by global developmental delay apparent in the first six months of life, followed by onset of seizures between 21 months and 4 years. Disease features include moderate-to-severe intellectual disability, poor speech, delayed walking, and ataxia.

OUTRAS DOENÇAS (2)
intellectual developmental disorder 60 with seizuresepilepsy with myoclonic atonic seizures
HGNC:564UniProt:Q96CW1
CACNA1HVoltage-dependent T-type calcium channel subunit alpha-1HCandidate gene tested inTolerante
FUNÇÃO

Voltage-sensitive calcium channel that gives rise to T-type calcium currents. T-type calcium channels belong to the 'low-voltage activated (LVA)' group. A particularity of this type of channel is an opening at quite negative potentials, and a voltage-dependent inactivation (PubMed:27149520, PubMed:9670923, PubMed:9930755). T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle (Probabl

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
NCAM1 interactionsSmooth Muscle ContractionMechanical load activates signaling by PIEZO1 and integrins in osteocytes
MECANISMO DE DOENÇA

Epilepsy, idiopathic generalized 6

A disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain.

OUTRAS DOENÇAS (3)
hyperaldosteronism, familial, type IVchildhood absence epilepsyepilepsy, childhood absence, susceptibility to, 6
HGNC:1395UniProt:O95180
JRKJerky protein homologCandidate gene tested inDesconhecido
FUNÇÃO

May bind DNA

LOCALIZAÇÃO

Nucleus

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
14.4 TPM
Fibroblastos
13.5 TPM
Cérebro - Hemisfério cerebelar
13.4 TPM
Ovário
12.3 TPM
Linfócitos
11.4 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
childhood absence epilepsyjuvenile myoclonic epilepsy
HGNC:6199UniProt:O75564
GABRA1Gamma-aminobutyric acid receptor subunit alpha-1Candidate gene tested inAltamente restrito
FUNÇÃO

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:23909897, PubMed:25489750, PubMed:29950725, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMed:29950725, PubMed:30602789). When activated by GA

LOCALIZAÇÃO

Postsynaptic cell membraneCell membraneCytoplasmic vesicle membrane

VIAS BIOLÓGICAS (2)
GABA receptor activationSignaling by ERBB4
MECANISMO DE DOENÇA

Epilepsy, childhood absence 4

A subtype of idiopathic generalized epilepsy characterized by an onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3-Hz spike waves on EEG. Tonic-clonic seizures often develop in adolescence. Absence seizures may either remit or persist into adulthood.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
82.7 TPM
Brain Frontal Cortex BA9
58.5 TPM
Cerebelo
55.7 TPM
Córtex cerebral
31.1 TPM
Brain Anterior cingulate cortex BA24
23.3 TPM
OUTRAS DOENÇAS (5)
developmental and epileptic encephalopathy, 19obsolete Dravet syndromechildhood absence epilepsyjuvenile myoclonic epilepsy
HGNC:4075UniProt:P14867
CUX2Homeobox protein cut-like 2Candidate gene tested inAltamente restrito
FUNÇÃO

Transcription factor involved in the control of neuronal proliferation and differentiation in the brain. Regulates dendrite development and branching, dendritic spine formation, and synaptogenesis in cortical layers II-III. Binds to DNA in a sequence-specific manner

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 67

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE67 is an autosomal dominant form characterized by onset of seizures in infancy. Later onset of seizures in childhood may occur in some patients.

EXPRESSÃO TECIDUAL(Tecido-específico)
Córtex cerebral
16.2 TPM
Brain Frontal Cortex BA9
13.9 TPM
Próstata
12.2 TPM
Fígado
10.6 TPM
Brain Anterior cingulate cortex BA24
5.8 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 67Lennox-Gastaut syndrome
HGNC:19347UniProt:O14529
NEXMIFNeurite extension and migration factorCandidate gene tested inAltamente restrito
FUNÇÃO

Involved in neurite outgrowth by regulating cell-cell adhesion via the N-cadherin signaling pathway. May act by regulating expression of protein-coding genes, such as N-cadherins and integrin beta-1 (ITGB1)

LOCALIZAÇÃO

NucleusCytoplasm

MECANISMO DE DOENÇA

Intellectual developmental disorder, X-linked 98

A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. XLID98 patients show delayed psychomotor development, absent or poor speech development, and postnatal growth retardation, often with microcephaly. Some patients show autistic behavioral features, such as stereotypic hand movements and repetitive behaviors. Additional, more variable features include spasticity, axial hypotonia, seizures, drooling, gastroesophageal reflux, and lack of sphincter control.

INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (2)
X-linked intellectual disability, Cantagrel typeepilepsy with myoclonic atonic seizures
HGNC:29433UniProt:Q5QGS0
SLC2A1Solute carrier family 2, facilitated glucose transporter member 1Candidate gene tested inAltamente restrito
FUNÇÃO

Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake (PubMed:10227690, PubMed:10954735, PubMed:18245775, PubMed:19449892, PubMed:25982116, PubMed:27078104, PubMed:32860739). Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses (PubMed:18245775, PubMed:19449892). Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative trans

LOCALIZAÇÃO

Cell membraneMelanosomePhotoreceptor inner segment

VIAS BIOLÓGICAS (3)
Vitamin C (ascorbate) metabolismCellular hexose transportRegulation of insulin secretion
MECANISMO DE DOENÇA

GLUT1 deficiency syndrome 1

A neurologic disorder showing wide phenotypic variability. The most severe 'classic' phenotype comprises infantile-onset epileptic encephalopathy associated with delayed development, acquired microcephaly, motor incoordination, and spasticity. Onset of seizures, usually characterized by apneic episodes, staring spells, and episodic eye movements, occurs within the first 4 months of life. Other paroxysmal findings include intermittent ataxia, confusion, lethargy, sleep disturbance, and headache. Varying degrees of cognitive impairment can occur, ranging from learning disabilities to severe intellectual disability.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
703.8 TPM
Skin Not Sun Exposed Suprapubic
272.6 TPM
Skin Sun Exposed Lower leg
265.8 TPM
Vagina
176.1 TPM
Esôfago - Mucosa
154.8 TPM
OUTRAS DOENÇAS (8)
childhood onset GLUT1 deficiency syndrome 2hereditary cryohydrocytosis with reduced stomatindystonia 9encephalopathy due to GLUT1 deficiency
HGNC:11005UniProt:P11166
MAPK10Mitogen-activated protein kinase 10Candidate gene tested inRestrito
FUNÇÃO

Serine/threonine-protein kinase involved in various processes such as neuronal proliferation, differentiation, migration and programmed cell death. Extracellular stimuli such as pro-inflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK10/JNK3. In turn, MAPK10/JNK3 phosphorylates a number of transcription f

LOCALIZAÇÃO

CytoplasmMembraneNucleusMitochondrion

VIAS BIOLÓGICAS (3)
Oxidative Stress Induced SenescenceFCERI mediated MAPK activationJNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
40.5 TPM
Córtex cerebral
29.8 TPM
Brain Anterior cingulate cortex BA24
21.9 TPM
Cérebro - Hemisfério cerebelar
19.8 TPM
Cerebelo
16.9 TPM
OUTRAS DOENÇAS (1)
Lennox-Gastaut syndrome
HGNC:6872UniProt:P53779
FRRS1LDOMON domain-containing protein FRRS1LCandidate gene tested inTolerante
FUNÇÃO

Important modulator of glutamate signaling pathway

LOCALIZAÇÃO

Cell membraneSynapse

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 37

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE37 is an autosomal recessive, severe form manifesting in the first years of life. Affected individuals show hyperkinetic movement disorder with choreoathetosis, spasticity, rigidity, intellectual disability, absent speech, and impaired volitional movements.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
53.7 TPM
Cerebelo
43.9 TPM
Brain Frontal Cortex BA9
29.1 TPM
Brain Nucleus accumbens basal ganglia
27.6 TPM
Córtex cerebral
22.6 TPM
OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy, 37developmental and/or epileptic encephalopathy with spike-wave activation in sleepautosomal recessive non-syndromic intellectual disability
HGNC:1362UniProt:Q9P0K9
SYNGAP1Ras/Rap GTPase-activating protein SynGAPCandidate gene tested inAltamente restrito
FUNÇÃO

Major constituent of the PSD essential for postsynaptic signaling. Inhibitory regulator of the Ras-cAMP pathway. Member of the NMDAR signaling complex in excitatory synapses, it may play a role in NMDAR-dependent control of AMPAR potentiation, AMPAR membrane trafficking and synaptic plasticity. Regulates AMPAR-mediated miniature excitatory postsynaptic currents. Exhibits dual GTPase-activating specificity for Ras and Rap. May be involved in certain forms of brain injury, leading to long-term lea

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Regulation of RAS by GAPs
MECANISMO DE DOENÇA

Intellectual developmental disorder, autosomal dominant 5

A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD5 patients show global developmental delay with delayed motor development, hypotonia, moderate-to-severe intellectual disability, and severe language impairment. Epilepsy and autism can be present in some patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
62.9 TPM
Útero
39.4 TPM
Fallopian Tube
38.5 TPM
Ovário
38.3 TPM
Cervix Endocervix
33.9 TPM
OUTRAS DOENÇAS (3)
intellectual disability, autosomal dominant 5epilepsy with myoclonic atonic seizuresundetermined early-onset epileptic encephalopathy
HGNC:11497UniProt:Q96PV0
ADORA2AAdenosine receptor A2aCandidate gene tested inTolerante
FUNÇÃO

Receptor for adenosine (By similarity). The activity of this receptor is mediated by G proteins which activate adenylyl cyclase (By similarity)

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (3)
G alpha (s) signalling eventsSurfactant metabolismAdenosine P1 receptors
OUTRAS DOENÇAS (1)
acute encephalopathy with biphasic seizures and late reduced diffusion
HGNC:263UniProt:P29274
CACNA1AVoltage-dependent P/Q-type calcium channel subunit alpha-1ACandidate gene tested inAltamente restrito
FUNÇÃO

Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1A gives rise to P and/or Q-type calcium currents. P/Q-type calcium channels belong to the 'high-voltage activated' (HVA) group and are specifically blocked by the spider omega-agatoxin-IVA

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Presynaptic depolarization and calcium channel openingRegulation of insulin secretion
MECANISMO DE DOENÇA

Spinocerebellar ataxia 6

Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA6 is an autosomal dominant cerebellar ataxia (ADCA), mainly caused by expansion of a CAG repeat in the coding region of CACNA1A. There seems to be a correlation between the repeat number and earlier onset of the disorder.

OUTRAS DOENÇAS (9)
migraine, familial hemiplegic, 1episodic ataxia type 2developmental and epileptic encephalopathy, 42spinocerebellar ataxia type 6
HGNC:1388UniProt:O00555
SRPX2Sushi repeat-containing protein SRPX2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a ligand for the urokinase plasminogen activator surface receptor. Plays a role in angiogenesis by inducing endothelial cell migration and the formation of vascular network (cords). Involved in cellular migration and adhesion. Increases the phosphorylation levels of FAK. Interacts with and increases the mitogenic activity of HGF. Promotes synapse formation. May have a role in the perisylvian region, critical for language and cognitive development

LOCALIZAÇÃO

SecretedCytoplasmCell surfaceSynapse

MECANISMO DE DOENÇA

Rolandic epilepsy, impaired intellectual development, and speech dyspraxia, X-linked

A condition characterized by the association of rolandic seizures with oral and speech dyspraxia, and intellectual disability. Rolandic seizures occur during a period of significant brain maturation. During this time, dysfunction of neural network activities such as focal discharges may be associated with specific developmental disabilities resulting in specific cognitive impairments of language, visuo-spatial abilities or attention.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
40.5 TPM
Fibroblastos
35.2 TPM
Adipose Visceral Omentum
34.4 TPM
Nervo tibial
29.5 TPM
Mama
21.9 TPM
OUTRAS DOENÇAS (4)
rolandic epilepsy, intellectual disability, and speech dyspraxia, X-linkedrolandic epilepsy-speech dyspraxia syndromeself-limited epilepsy with centrotemporal spikesbilateral perisylvian polymicrogyria
HGNC:30668UniProt:O60687
GALGalanin peptidesDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Endocrine hormone of the central and peripheral nervous systems that binds and activates the G protein-coupled receptors GALR1, GALR2, and GALR3. This small neuropeptide may regulate diverse physiologic functions including contraction of smooth muscle of the gastrointestinal and genitourinary tract, growth hormone and insulin release and adrenal secretion

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (2)
G alpha (i) signalling eventsPeptide ligand-binding receptors
MECANISMO DE DOENÇA

Epilepsy, familial temporal lobe, 8

A focal form of epilepsy characterized by recurrent seizures that arise from foci within the temporal lobe. Seizures are usually accompanied by sensory symptoms, most often auditory in nature.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pituitária
578.3 TPM
Hipotálamo
24.3 TPM
Cólon sigmoide
13.7 TPM
Esôfago - Muscular
7.3 TPM
Skin Not Sun Exposed Suprapubic
5.9 TPM
OUTRAS DOENÇAS (1)
familial temporal lobe epilepsy 8
HGNC:HGNC:4114UniProt:P22466
CHRNB2Neuronal acetylcholine receptor subunit beta-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensiti

LOCALIZAÇÃO

Synaptic cell membraneCell membrane

VIAS BIOLÓGICAS (3)
Highly calcium permeable nicotinic acetylcholine receptorsHighly sodium permeable postsynaptic acetylcholine nicotinic receptorsHighly calcium permeable postsynaptic nicotinic acetylcholine receptors
MECANISMO DE DOENÇA

Epilepsy, nocturnal frontal lobe, 3

An autosomal dominant focal epilepsy characterized by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements.

OUTRAS DOENÇAS (2)
autosomal dominant nocturnal frontal lobe epilepsy 3autosomal dominant nocturnal frontal lobe epilepsy
HGNC:1962UniProt:P17787
CHRNA4Neuronal acetylcholine receptor subunit alpha-4Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensiti

LOCALIZAÇÃO

Synaptic cell membraneCell membrane

VIAS BIOLÓGICAS (3)
Highly calcium permeable nicotinic acetylcholine receptorsHighly sodium permeable postsynaptic acetylcholine nicotinic receptorsHighly calcium permeable postsynaptic nicotinic acetylcholine receptors
MECANISMO DE DOENÇA

Epilepsy, nocturnal frontal lobe, 1

An autosomal dominant focal epilepsy characterized by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements.

OUTRAS DOENÇAS (3)
autosomal dominant nocturnal frontal lobe epilepsy 1autosomal dominant nocturnal frontal lobe epilepsytobacco addiction, susceptibility to
HGNC:1958UniProt:P43681
KCNT1Potassium channel subfamily T member 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Sodium-activated K(+) channel (PubMed:37494189). Acts as an important mediator of neuronal membrane excitability (PubMed:37494189). Contributes to the delayed outward currents (By similarity). Regulates neuronal bursting in sensory neurons (By similarity). Contributes to synaptic development and plasticity (By similarity)

LOCALIZAÇÃO

Cell membrane

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 14

A rare epileptic encephalopathy of infancy that combines pharmacoresistant seizures with developmental delay. This severe neurologic disorder is characterized by onset in the first 6 months of life of refractory focal seizures and arrest of psychomotor development. Ictal EEG shows discharges that arise randomly from various areas of both hemispheres and migrate from one brain region to another.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
94.7 TPM
Cérebro - Hemisfério cerebelar
80.1 TPM
Córtex cerebral
44.1 TPM
Brain Frontal Cortex BA9
30.4 TPM
Baço
20.2 TPM
OUTRAS DOENÇAS (4)
developmental and epileptic encephalopathy, 14autosomal dominant nocturnal frontal lobe epilepsy 5malignant migrating partial seizures of infancyautosomal dominant nocturnal frontal lobe epilepsy
HGNC:18865UniProt:Q5JUK3
CHD2ATP-dependent chromatin remodeler CHD2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

ATP-dependent chromatin-remodeling factor that specifically binds to the promoter of target genes, leading to chromatin remodeling, possibly by promoting deposition of histone H3.3. Involved in myogenesis via interaction with MYOD1: binds to myogenic gene regulatory sequences and mediates incorporation of histone H3.3 prior to the onset of myogenic gene expression, promoting their expression (By similarity)

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 94

A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE94 is an autosomal dominant, severe form characterized by onset of multiple seizure types in the first few years of life.

INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy 94epilepsy with myoclonic atonic seizuresLennox-Gastaut syndrome
HGNC:1917UniProt:O14647
LGI1Leucine-rich glioma-inactivated protein 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Regulates voltage-gated potassium channels assembled from KCNA1, KCNA4 and KCNAB1. It slows down channel inactivation by precluding channel closure mediated by the KCNAB1 subunit. Ligand for ADAM22 that positively regulates synaptic transmission mediated by AMPA-type glutamate receptors (By similarity). Plays a role in suppressing the production of MMP1/3 through the phosphatidylinositol 3-kinase/ERK pathway. May play a role in the control of neuroblastoma cell survival

LOCALIZAÇÃO

SecretedSynapseCytoplasmGolgi apparatusEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
LGI-ADAM interactions
MECANISMO DE DOENÇA

Epilepsy, familial temporal lobe, 1

A focal form of epilepsy characterized by recurrent seizures that arise from foci within the temporal lobe. Seizures are usually accompanied by sensory symptoms, most often auditory in nature.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
21.0 TPM
Cerebelo
16.6 TPM
Brain Caudate basal ganglia
15.7 TPM
Brain Nucleus accumbens basal ganglia
14.9 TPM
Brain Frontal Cortex BA9
14.5 TPM
OUTRAS DOENÇAS (2)
epilepsy, familial temporal lobe, 1autosomal dominant epilepsy with auditory features
HGNC:6572UniProt:O95970
NPRL3GATOR1 complex protein NPRL3Disease-causing germline mutation(s) inRestrito
FUNÇÃO

As a component of the GATOR1 complex functions as an inhibitor of the amino acid-sensing branch of the mTORC1 pathway (PubMed:23723238, PubMed:29590090, PubMed:35338845). In response to amino acid depletion, the GATOR1 complex has GTPase activating protein (GAP) activity and strongly increases GTP hydrolysis by RagA/RRAGA (or RagB/RRAGB) within heterodimeric Rag complexes, thereby turning them into their inactive GDP-bound form, releasing mTORC1 from lysosomal surface and inhibiting mTORC1 signa

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Amino acids regulate mTORC1
EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
54.0 TPM
Testículo
52.7 TPM
Sangue
52.6 TPM
Cerebelo
46.3 TPM
Nervo tibial
45.0 TPM
OUTRAS DOENÇAS (2)
epilepsy, familial focal, with variable foci 3familial focal epilepsy with variable foci
HGNC:14124UniProt:Q12980
DNM1Dynamin-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the hydrolysis of GTP and utilizes this energy to mediate vesicle scission and participates in many forms of endocytosis, such as clathrin-mediated endocytosis or synaptic vesicle endocytosis as well as rapid endocytosis (RE) (PubMed:15703209, PubMed:20428113, PubMed:29668686, PubMed:8101525, PubMed:8910402, PubMed:9362482). Associates to the membrane, through lipid binding, and self-assembles into rings and stacks of interconnected rings through oligomerization to form a helical polym

LOCALIZAÇÃO

Cell membraneMembrane, clathrin-coated pitCytoplasmic vesiclePresynapseCytoplasmic vesicle, secretory vesicle, chromaffin granule

VIAS BIOLÓGICAS (7)
Gap junction degradationFormation of annular gap junctionsRetrograde neurotrophin signallingRecycling pathway of L1MHC class II antigen presentation
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 31A

An autosomal dominant epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
373.8 TPM
Cérebro - Hemisfério cerebelar
367.4 TPM
Brain Frontal Cortex BA9
260.3 TPM
Córtex cerebral
254.5 TPM
Brain Anterior cingulate cortex BA24
127.4 TPM
OUTRAS DOENÇAS (4)
developmental and epileptic encephalopathy, 31Adevelopmental and epileptic encephalopathy, 31Bundetermined early-onset epileptic encephalopathyLennox-Gastaut syndrome
HGNC:2972UniProt:Q05193
NPRL2GATOR1 complex protein NPRL2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Catalytic component of the GATOR1 complex, a multiprotein complex that functions as an inhibitor of the amino acid-sensing branch of the mTORC1 pathway (PubMed:23723238, PubMed:29590090, PubMed:35338845, PubMed:38006878). In response to amino acid depletion, the GATOR1 complex has GTPase activating protein (GAP) activity and strongly increases GTP hydrolysis by RagA/RRAGA (or RagB/RRAGB) within heterodimeric Rag complexes, thereby turning them into their inactive GDP-bound form, releasing mTORC1

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Amino acids regulate mTORC1
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
68.2 TPM
Cérebro - Hemisfério cerebelar
65.3 TPM
Pituitária
57.7 TPM
Ovário
45.2 TPM
Cervix Endocervix
44.3 TPM
OUTRAS DOENÇAS (2)
epilepsy, familial focal, with variable foci 2familial focal epilepsy with variable foci
HGNC:24969UniProt:Q8WTW4
CPA6Carboxypeptidase A6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the proteolytic inactivation of enkephalins and neurotensin in some brain areas. May convert inactive angiotensin I into the biologically active angiotensin II (PubMed:18178555). Releases a C-terminal amino acid, with preference for large hydrophobic C-terminal amino acids and shows only very weak activity toward small amino acids and histidine (PubMed:20855895)

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

OUTRAS DOENÇAS (4)
familial temporal lobe epilepsy 5febrile seizures, familial, 11familial mesial temporal lobe epilepsygeneralized epilepsy with febrile seizures plus
HGNC:17245UniProt:Q8N4T0
SLC6A1Sodium- and chloride-dependent GABA transporter 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Mediates transport of gamma-aminobutyric acid (GABA) together with sodium and chloride and is responsible for the reuptake of GABA from the synapse (PubMed:30132828). The translocation of GABA, however, may also occur in the reverse direction leading to the release of GABA (By similarity). The direction and magnitude of GABA transport is a consequence of the prevailing thermodynamic conditions, determined by membrane potential and the intracellular and extracellular concentrations of Na(+), Cl(-

LOCALIZAÇÃO

Cell membranePresynapse

VIAS BIOLÓGICAS (2)
SLC-mediated transport of neurotransmittersReuptake of GABA
MECANISMO DE DOENÇA

Myoclonic-atonic epilepsy

A form of epilepsy characterized by myoclonic-atonic and absence seizures, appearing in early childhood. Patients have delayed development before the onset of seizures and show varying degrees of intellectual disability following seizure onset.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
126.4 TPM
Brain Anterior cingulate cortex BA24
120.3 TPM
Córtex cerebral
111.2 TPM
Brain Caudate basal ganglia
105.3 TPM
Brain Nucleus accumbens basal ganglia
90.0 TPM
OUTRAS DOENÇAS (2)
epilepsy with myoclonic atonic seizuresautosomal dominant non-syndromic intellectual disability
HGNC:11042UniProt:P30531
DEPDC5GATOR1 complex protein DEPDC5Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

As a component of the GATOR1 complex functions as an inhibitor of the amino acid-sensing branch of the mTORC1 pathway (PubMed:23723238, PubMed:25457612, PubMed:29590090, PubMed:29769719, PubMed:31548394, PubMed:35338845). In response to amino acid depletion, the GATOR1 complex has GTPase activating protein (GAP) activity and strongly increases GTP hydrolysis by RagA/RRAGA (or RagB/RRAGB) within heterodimeric Rag complexes, thereby turning them into their inactive GDP-bound form, releasing mTORC1

LOCALIZAÇÃO

Lysosome membraneCytoplasm, cytosolCytoplasm, perinuclear region

VIAS BIOLÓGICAS (1)
Amino acids regulate mTORC1
MECANISMO DE DOENÇA

Epilepsy, familial focal, with variable foci 1

An autosomal dominant form of epilepsy characterized by focal seizures arising from different cortical regions in different family members. Many patients have an aura and show automatisms during the seizures, whereas others may have nocturnal seizures. There is often secondary generalization. Some patients show abnormal interictal EEG, and some patients may have intellectual disability or autism spectrum disorders. Seizure onset usually occurs in the first or second decades, although later onset has been reported, and there is phenotypic variability within families. Penetrance of the disorder is incomplete.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
16.3 TPM
Testículo
13.5 TPM
Linfócitos
10.8 TPM
Baço
10.6 TPM
Cervix Ectocervix
10.5 TPM
OUTRAS DOENÇAS (5)
epilepsy, familial focal, with variable foci 1developmental and epileptic encephalopathy 111familial focal epilepsy with variable fociundetermined early-onset epileptic encephalopathy
HGNC:18423UniProt:O75140
GABRB3Gamma-aminobutyric acid receptor subunit beta-3Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Beta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:14993607, PubMed:18514161, PubMed:22243422, PubMed:22303015, PubMed:24909990, PubMed:26950270, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (PubMe

LOCALIZAÇÃO

Postsynaptic cell membraneCell membraneCytoplasmic vesicle membrane

VIAS BIOLÓGICAS (2)
GABA receptor activationSignaling by ERBB4
MECANISMO DE DOENÇA

Epilepsy, childhood absence 5

A subtype of idiopathic generalized epilepsy characterized by an onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3-Hz spike waves on EEG. Tonic-clonic seizures often develop in adolescence. Absence seizures may either remit or persist into adulthood.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
21.5 TPM
Cérebro - Hemisfério cerebelar
16.5 TPM
Brain Nucleus accumbens basal ganglia
15.1 TPM
Pituitária
13.8 TPM
Córtex cerebral
13.7 TPM
OUTRAS DOENÇAS (4)
developmental and epileptic encephalopathy, 43Lennox-Gastaut syndromechildhood absence epilepsyepilepsy, childhood absence, susceptibility to, 5
HGNC:4083UniProt:P28472
KCNMA1Calcium-activated potassium channel subunit alpha-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+) (PubMed:14523450, PubMed:29330545, PubMed:31152168). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of sys

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (4)
cGMP effectsCa2+ activated K+ channelsAcetylcholine inhibits contraction of outer hair cellsSensory processing of sound by inner hair cells of the cochlea
MECANISMO DE DOENÇA

Paroxysmal non-kinesigenic dyskinesia 3 with or without generalized epilepsy

An autosomal dominant neurologic disorder characterized by absence seizures, generalized tonic-clonic seizures, paroxysmal nonkinesigenic dyskinesia and involuntary dystonic or choreiform movements. Onset is usually in childhood. Patients may have seizures only, dyskinesia only, or both.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
43.8 TPM
Cólon sigmoide
36.4 TPM
Artéria tibial
30.3 TPM
Esôfago - Muscular
29.5 TPM
Esôfago - Junção
29.3 TPM
OUTRAS DOENÇAS (4)
Liang-Wang syndromegeneralized epilepsy-paroxysmal dyskinesia syndromecerebellar atrophy, developmental delay, and seizuresepilepsy, idiopathic generalized, susceptibility to, 16
HGNC:6284UniProt:Q12791
TBC1D24TBC1 domain family member 24Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May act as a GTPase-activating protein for Rab family protein(s) (PubMed:20727515, PubMed:20797691). Involved in neuronal projections development, probably through a negative modulation of ARF6 function (PubMed:20727515). Involved in the regulation of synaptic vesicle trafficking (PubMed:31257402)

LOCALIZAÇÃO

Cell membraneCytoplasmCytoplasmic vesicle membranePresynapse

VIAS BIOLÓGICAS (1)
TBC/RABGAPs
MECANISMO DE DOENÇA

Familial infantile myoclonic epilepsy

A subtype of idiopathic epilepsy starting in early infancy and manifesting as myoclonic seizures, febrile convulsions, and tonic-clonic seizures.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
27.8 TPM
Cérebro - Hemisfério cerebelar
26.6 TPM
Brain Frontal Cortex BA9
11.4 TPM
Córtex cerebral
11.2 TPM
Pituitária
9.4 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (11)
familial infantile myoclonic epilepsyrolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndromeautosomal dominant nonsyndromic hearing loss 65autosomal recessive nonsyndromic hearing loss 86
HGNC:29203UniProt:Q9ULP9
CHRNA2Neuronal acetylcholine receptor subunit alpha-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensiti

LOCALIZAÇÃO

Synaptic cell membraneCell membrane

VIAS BIOLÓGICAS (2)
Highly calcium permeable nicotinic acetylcholine receptorsHighly calcium permeable postsynaptic nicotinic acetylcholine receptors
MECANISMO DE DOENÇA

Epilepsy, nocturnal frontal lobe, 4

An autosomal dominant focal epilepsy characterized by nocturnal seizures associated with fear sensation, tongue movements, and nocturnal wandering, closely resembling nightmares and sleep walking.

OUTRAS DOENÇAS (2)
autosomal dominant nocturnal frontal lobe epilepsy 4autosomal dominant nocturnal frontal lobe epilepsy
HGNC:1956UniProt:Q15822
GRIN2AGlutamate receptor ionotropic, NMDA 2ADisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+) (PubMed:20890276, PubMed:23933818, PubMed:23933819, PubMed:23933820, PubMed:24504326, PubMed:26875626, PubMed:26919761, PubMed:28242877, PubMed:36117210, PubMed:38538865, PubMed:8768735). NMDARs participate in synaptic plasticity for learning and memory formation by contributing to the slow phase of excita

LOCALIZAÇÃO

Cell projection, dendritic spineCell membraneSynapsePostsynaptic cell membraneCytoplasmic vesicle membrane

VIAS BIOLÓGICAS (1)
Assembly and cell surface presentation of NMDA receptors
MECANISMO DE DOENÇA

Epilepsy, focal, with speech disorder and with or without impaired intellectual development

An autosomal dominant, highly variable neurologic disorder. Features range from severe early-onset seizures associated with delayed psychomotor development, persistent speech difficulties, and intellectual disability to a more benign entity characterized by childhood onset of mild or asymptomatic seizures associated with transient speech difficulties followed by remission of seizures in adolescence and normal psychomotor development. The disorder encompasses several clinical entities, including Landau-Kleffner syndrome, epileptic encephalopathy with continuous spike and wave during slow-wave sleep, autosomal dominant rolandic epilepsy, intellectual disability and speech dyspraxia, and benign epilepsy with centrotemporal spikes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
17.0 TPM
Cérebro - Hemisfério cerebelar
14.8 TPM
Cerebelo
12.7 TPM
Córtex cerebral
11.3 TPM
Brain Anterior cingulate cortex BA24
7.2 TPM
OUTRAS DOENÇAS (5)
early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutationdevelopmental and/or epileptic encephalopathy with spike-wave activation in sleeprolandic epilepsy-speech dyspraxia syndromeself-limited epilepsy with centrotemporal spikes
HGNC:4585UniProt:Q12879
GABRG2Gamma-aminobutyric acid receptor subunit gamma-2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Gamma subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:14993607, PubMed:16412217, PubMed:23909897, PubMed:2538761, PubMed:25489750, PubMed:27864268, PubMed:29950725, PubMed:30602789). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit in

LOCALIZAÇÃO

Postsynaptic cell membraneCell membraneCell projection, dendriteCytoplasmic vesicle membrane

VIAS BIOLÓGICAS (2)
GABA receptor activationSignaling by ERBB4
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 74

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE74 is an autosomal dominant form with onset in the first year of life.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
20.3 TPM
Brain Frontal Cortex BA9
19.4 TPM
Cerebelo
15.3 TPM
Córtex cerebral
10.6 TPM
Brain Nucleus accumbens basal ganglia
7.7 TPM
OUTRAS DOENÇAS (7)
febrile seizures, familial, 8developmental and epileptic encephalopathy, 74obsolete Dravet syndromechildhood absence epilepsy
HGNC:4087UniProt:P18507

Medicamentos e terapias

RUFINAMIDEPhase 4

Mecanismo: Sodium channel alpha subunit blocker

CANNABIDIOLPhase 4

Mecanismo: Cannabinoid CB1 receptor negative allosteric modulator

TOPIRAMATEPhase 4

Mecanismo: Sodium channel alpha subunit blocker

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

910 variantes patogênicas registradas no ClinVar.

🧬 SCN3A: NM_006922.4(SCN3A):c.603-1G>A ()
🧬 SCN3A: NM_006922.4(SCN3A):c.4349T>A (p.Ile1450Asn) ()
🧬 SCN3A: NM_006922.4(SCN3A):c.4200T>G (p.Phe1400Leu) ()
🧬 SCN3A: NM_006922.4(SCN3A):c.4456A>G (p.Thr1486Ala) ()
🧬 SCN3A: NM_006922.4(SCN3A):c.3616A>C (p.Asn1206His) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 2 variantes classificadas pelo ClinVar.

2
Patogênica (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
AMDHD2: NM_001694.4(ATP6V0C):c.283G>A (p.Ala95Thr) [Likely pathogenic]
KCNT1: NM_020822.3(KCNT1):c.1193G>A (p.Arg398Gln) [Pathogenic/Likely pathogenic]

Vias biológicas (Reactome)

67 vias biológicas associadas aos genes desta condição.

Interaction between L1 and Ankyrins Phase 0 - rapid depolarisation Sensory perception of sweet, bitter, and umami (glutamate) taste Reelin signalling pathway Factors involved in megakaryocyte development and platelet production Class B/2 (Secretin family receptors) G alpha (s) signalling events MECP2 regulates transcription of neuronal ligands Nef mediated downregulation of CD28 cell surface expression Nef Mediated CD4 Down-regulation Retrograde neurotrophin signalling Nef Mediated CD8 Down-regulation Gap junction degradation Formation of annular gap junctions MHC class II antigen presentation EPH-ephrin mediated repulsion of cells Trafficking of GluR2-containing AMPA receptors Recycling pathway of L1 WNT5A-dependent internalization of FZD4 WNT5A-dependent internalization of FZD2, FZD5 and ROR2 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis VLDLR internalisation and degradation LDL clearance Potential therapeutics for SARS Dengue Virus Attachment and Entry NCAM1 interactions Smooth Muscle Contraction Mechanical load activates signaling by PIEZO1 and integrins in osteocytes Signaling by ERBB4 GABA receptor activation Cellular hexose transport Vitamin C (ascorbate) metabolism Regulation of insulin secretion Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) Lactose synthesis Oxidative Stress Induced Senescence FCERI mediated MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 Activation of the AP-1 family of transcription factors Regulation of RAS by GAPs NGF-independant TRKA activation Adenosine P1 receptors Surfactant metabolism Presynaptic depolarization and calcium channel opening Peptide ligand-binding receptors G alpha (i) signalling events Highly sodium permeable postsynaptic acetylcholine nicotinic receptors Highly calcium permeable postsynaptic nicotinic acetylcholine receptors Highly calcium permeable nicotinic acetylcholine receptors LGI-ADAM interactions Amino acids regulate mTORC1 Toll Like Receptor 4 (TLR4) Cascade SLC-mediated transport of neurotransmitters Reuptake of GABA Ca2+ activated K+ channels cGMP effects Sensory processing of sound by inner hair cells of the cochlea Acetylcholine inhibits contraction of outer hair cells TBC/RABGAPs Unblocking of NMDA receptors, glutamate binding and activation Neurexins and neuroligins Synaptic adhesion-like molecules MECP2 regulates neuronal receptors and channels Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado3
Medicamentos catalogadosEnsaios clínicos· 3 medicamentos · 0 ensaios
✓ Aprovados — podem ser usados hoje
RUFINAMIDECANNABIDIOLTOPIRAMATE
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome epilepsia de início na infância

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
7 papers (10 anos)
#1

Intellectual function and psychiatric comorbidities in patients with epilepsy with eyelid myoclonia.

Epilepsy & behavior : E&B2026 Mar

Epilepsy with Eyelid Myoclonia (EEM) is a rare childhood-onset epilepsy syndrome. There is limited data about cognitive function and psychiatric comorbidities in patients with EEM. A database of 134 patients with EEM was reviewed for patients who underwent neuropsychological testing. Psychiatric comorbidities and psychometric test scores were identified. Group comparison was performed between those who underwent neuropsychological testing and those who did not. In addition, we evaluated whether clinical factors were associated with IQ score. Fourteen patients underwent neuropsychological testing (12 females, 85.7%), with a median age at testing of 17 (range 7-22). Median IQ was 79 (range 56-110); 7 patients had below average IQ. Other median results of neuropsychometric measures were: Verbal Comprehension Index 85.5 (range 66-116), Perceptual Reasoning Index or Visual Spatial Index 81.5 (range 67-100), Working Memory Index 77 (range 54-100), Processing Speed Index 84 (range 53-94), and Reading Standardized Scores 84 (range 64-126). Common psychiatric comorbidities were anxiety (n = 10), depression (n = 7), ADHD (n = 6), and autism (n = 2). Those who underwent neuropsychological testing had a younger age of epilepsy onset, longer follow-up at our institution, and were more likely to have myoclonic seizures or psychosis than those who did not undergo neuropsychological testing. No clinical factors were statistically associated with IQ score. EEM is associated with a wide range of cognitive abilities, with half of our patients having a below average IQ. Psychiatric comorbidities were common. Identifying cognitive impairment and psychiatric comorbidities is crucial to implement appropriate management strategies.

#2

Current and Future Treatment Strategies in Developmental and/or Epileptic Encephalopathy With Spike-Wave Activation in Sleep (DEE-SWAS): A Time for Precision Medicine?

Pediatric neurology2025 Sep

Developmental and/or epileptic encephalopathy with spike-wave activation in sleep (D/EE-SWAS) is a childhood-onset epilepsy syndrome characterized by cognitive regression or stagnation and marked activation of epileptiform activity during sleep. DEE-SWAS refers to cases with pre-existing neurodevelopmental disorders, whereas EE-SWAS is applied when development was initially normal before the onset of epileptic encephalopathy. This syndrome comprises approximately 0.2%-1.3% of all pediatric epilepsies. D/EE-SWAS etiology includes structural anomalies and autoimmune and genetic causes, although etiology frequently remains unknown. The active epileptic process in a developing brain results in impairment of cognitive functions and behavior. For this reason, early recognition of the electroclinical syndrome and treatment initiation is extremely relevant for the long-term cognitive outcome. Typically, the available therapeutic strategies consisted of low-quality evidence and limited effectiveness, such as combinations of antiseizure medications and steroids, which were based on syndromic diagnoses rather than etiology-driven hypotheses. Over the last years, treatment has been shifting toward precision medicine approaches, with an increasing proportion of genetic diagnosis, new evidence supporting the efficacy of the surgical option in selected patients, and specific targeted treatments, such as l-serine in GRIN-related disorders. Additionally, this coexists with ongoing clinical trials with syndrome-specific design for D/EE-SWAS. This narrative review aims to summarize the evidence on treatments for D/EE-SWAS, provide updates on drugs currently in development, and explore precision medicine approaches for this syndrome, seeking to combine both syndrome- and etiology-driven treatment strategies.

#3

Epilepsy with myoclonic-atonic seizures: an update on genetic causes, nosological limits, and treatment strategies.

The Lancet. Neurology2025 Apr

Epilepsy with myoclonic-atonic seizures is a childhood-onset epilepsy syndrome characterised by a range of seizure types, including myoclonic-atonic, atonic, myoclonic, absence, and generalised tonic-clonic seizures. The causes and outcomes of this syndrome are highly variable, with many uncertainties surrounding its classification and prognosis. Traditional antiseizure medications and the ketogenic diet remain the main treatment options. Although two-thirds of children attain remission from seizures without cognitive or behavioural sequelae, some continue to have drug-resistant seizures, intellectual disability, and behavioural problems. The identification of single-gene causes in a substantial subset of patients highlights the importance of genetic testing for development of personalised treatment strategies. However, diagnostic complexities have hindered the development of trials for new therapies. Better recognition of the distinct features of epilepsy with myoclonic-atonic seizures, combined with advances in molecular genetic testing, will pave the way for more focused clinical research and drug development. Future studies should aim to identify genetic causes and tailor treatment options, offering hope for improved long-term outcomes.

#4

Efficacy and Tolerability of Lacosamide in Lennox-Gastaut Syndrome: A Systematic Review and Meta-analysis.

Journal of neurosciences in rural practice2022 Jan

Purpose  Lennox-Gastaut syndrome (LGS) is one of the most difficult to treat childhood-onset epileptic encephalopathies. There is growing evidence that lacosamide is safe and efficacious in patients and adults with refractory epilepsy. However, the evidence regarding the efficacy of lacosamide in LGS is controversial so far. We aimed to evaluate the efficacy and tolerability of lacosamide in patients with LGS. Methods  We conducted a systematic review on MEDLINE, EMBASE, COCHRANE CENTRAL, Google Scholar, and Web of Science, collating all available literature till July 31, 2020. The qualitative review included case reports, case series, and both controlled/uncontrolled trials as well as retrospective studies, but for determining pooled estimates, we only included studies with a sample size of 5 or more. The primary outcome was the efficacy of lacosamide in patients with LGS. Clinical variables related to efficacy and adverse events attributed to lacosamide were extracted from each publication. The pooled estimate of variables related to these parameters was performed using a random-effect model. Results  Of the 68 items identified by the search, 14 were reviewed as full-text. Eleven articles including two prospective and six retrospective studies fulfilled eligibility criteria and described outcomes in 81 patients (42 adults, 39 children, 60% male, range-1.4-61 years). On average, 35.2%, 27.9%, 7.3%, and 29.4% patients had > 50% reduction, < 50% reduction, no change, and worsening of seizure frequency, respectively. Although 36% of patients had adverse events like somnolence, behavioral abnormalities including irritability, aggressiveness, nausea, tremor, memory problems, dizziness, gastrointestinal discomfort, vomiting, and weight loss, no serious adverse events were noted. Conclusion  The evidence available in the current literature is not sufficient to support or refute the use of lacosamide in patients with LGS. Although it is one of the possible therapeutic options worth exploring in patients with LGS, caution is still necessary, as there are reports of worsening of seizure frequency in some patients.

#5

PCDH19-Related Epilepsy Syndrome: A Comprehensive Clinical Review.

Pediatric neurology2020 Apr

PCDH19-related epilepsy is a distinct childhood-onset epilepsy syndrome characterized by brief clusters of febrile and afebrile seizures with onset primarily before the age of three years, cognitive impairment, autistic traits, and behavioral abnormalities. PCDH19 gene is located in Xq22 and produces nonclustered delta protocadherin. This disorder primarily manifests in heterozygote females due to random X chromosome inactivation leading to somatic mosaicism and abnormal cellular interference between cells with and without delta-protocadherin. This article reviews the clinical features based on a comprehensive literature review (MEDLINE using PubMed and OvidSP vendors with appropriate keywords to incorporate recent evidence), personal practice, and experience. Significant progress has been made in the past 10 years, including identification of the gene responsible for the condition, characterization of clinical phenotypes, and development of animal models. More rigorous studies involving quality-of-life measures as well as standardized neuropsychiatric testing are necessary to understand the full spectrum of the disease. The recent discovery of allopregnanolone deficiency in patients with PCDH19-related epilepsy leads to opportunities in precision therapy. A phase 3 clinical study is currently active to evaluate the efficacy, safety, and tolerability of adjunctive ganaxolone (an allopregnanolone analog) therapy.

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome epilepsia de início na infância.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Síndrome epilepsia de início na infância

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Intellectual function and psychiatric comorbidities in patients with epilepsy with eyelid myoclonia.
    Epilepsy &amp; behavior : E&amp;B· 2026· PMID 41621152mais citado
  2. Current and Future Treatment Strategies in Developmental and/or Epileptic Encephalopathy With Spike-Wave Activation in Sleep (DEE-SWAS): A Time for Precision Medicine?
    Pediatric neurology· 2025· PMID 40664003mais citado
  3. Epilepsy with myoclonic-atonic seizures: an update on genetic causes, nosological limits, and treatment strategies.
    The Lancet. Neurology· 2025· PMID 40120618mais citado
  4. Efficacy and Tolerability of Lacosamide in Lennox-Gastaut Syndrome: A Systematic Review and Meta-analysis.
    Journal of neurosciences in rural practice· 2022· PMID 35110918mais citado
  5. PCDH19-Related Epilepsy Syndrome: A Comprehensive Clinical Review.
    Pediatric neurology· 2020· PMID 32057594mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98259(Orphanet)
  2. MONDO:0020072(MONDO)
  3. Epilepsia(PCDT · Ministério da Saúde)
  4. GARD:19437(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q5382985(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Síndrome epilepsia de início na infância
Compêndio · Raras BR

Síndrome epilepsia de início na infância

ORPHA:98259 · MONDO:0020072
🇧🇷 Brasil SUS
Geral
Medicamentos
3 registrados
MedGen
UMLS
C2733190
Repurposing
14 candidatos
aminohydroxybutyric-acidcarbonic anhydrase inhibitor
diclofenamidesuccinimide antiepileptic
ethosuximideglutamate receptor antagonist
+11 outros
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades